Harrow: Positive And Negative Adjustments After Investor Day Offset Each Other

Harrow is a small biotech company focused on acquiring and commercializing ophthalmic pharmaceutical products in the US.
Investor's Business Daily on MSN

Harrow Earns Relative Strength Rating Upgrade

Over 100 years of market history shows that the best-performing stocks typically have an 80 or better RS Rating in the early ...
Yahoo Finance

Harrow Announces Pricing of $250.0 Million Offering of Senior Unsecured Notes Due 2030

NASHVILLE, Tenn., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the pricing of its private ...
Business Wire

Harrow to Report Fourth Quarter and Year-End 2024 Financial Results After Market Close on March 17, 2025

NASHVILLE, Tenn.--(BUSINESS WIRE)--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that it will report its financial results for the fourth quarter and ...
Business Wire

Harrow Announces Fourth Quarter and Year-End 2022 Financial Results

NASHVILLE, Tenn.--(BUSINESS WIRE)--Harrow (NASDAQ: HROW), a leading U.S. eyecare pharmaceutical company, today announced results for the fourth quarter and year ended December 31, 2022. The Company ...
Business Insider

Harrow Announces Offering of $250.0 Million Senior Unsecured Notes Due 2030

Announces Commitment for New $40 Million Revolving Credit Facility Issues Conditional Notice of Redemption of 11.875% Senior Notes due 2027 NASHVILLE, Tenn., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Harrow ...